Agree that the additional trial sites in Turkey is a positive move.
At $50m EV and a P2B readout late this year, PER does offer great value at these prices.
Questions is what else does management have to keep momentum going?
Monkey tox study is almost expected to be good news.
But to get those 48c oppies in the money, we'll need a nice ramp leading into the P2B results.
.
-
- There are more pages in this discussion • 161 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
0.8¢ |
Change
0.000(0.00%) |
Mkt cap ! $8.699M | |||
| Open | High | Low | Value | Volume |
| 0.9¢ | 0.9¢ | 0.8¢ | $1.301K | 156.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 27 | 6745374 | 0.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.9¢ | 1257781 | 6 |
View Market Depth
| Last trade - 15.56pm 22/07/2025 (20 minute delay) ? |
| PER (ASX) Chart |